{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:14:24Z","timestamp":1788275664233,"version":"build-2803163510"},"reference-count":51,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Diabetes Invest"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Type 1 diabetes is defined by immune\u2010mediated beta\u2010cell failure and dependence on exogenous insulin. That definition is correct, but it may not fully describe many people seen in current clinical practice. Overweight and obesity are now common in type 1 diabetes, leading to variable combinations of high insulin requirement, hypertension, dyslipidemia, metabolic syndrome, metabolic dysfunction\u2010associated steatotic liver disease (MASLD), and increased cardiovascular and renal risk. These features have been termed double diabetes, but that term is descriptive rather than mechanistic. The overlap between type 1 and type 2 diabetes features may reflect overweight or obesity, effects of intensive insulin therapy (with treatment\u2010related hyperinsulinemia leading to disproportionate peripheral vs. hepatic insulin action), inherited or environmental factors leading to insulin resistance, glucagon dysregulation, ectopic fat, and inflammation. This review summarizes the epidemiology, pathophysiology, clinical consequences, and therapeutic implications of insulin\u2010resistant type 1 diabetes, reviewing the established precedent of amylin replacement and potential treatments including incretin receptor agonists and next\u2010generation amylin receptor agonists.<\/jats:p>","DOI":"10.1111\/jdi.70427","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:43:08Z","timestamp":1788273788000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Type 1 diabetes in the era of obesity: Pathophysiology and therapeutic implications"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3863-9267","authenticated-orcid":false,"given":"Zachary","family":"Bloomgarden","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Diabetes and Bone Disease Department of Medicine, Icahn School of Medicine at Mount Sinai  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"crossref","first-page":"427","DOI":"10.7326\/M22-3078","article-title":"Prevalence and management of obesity in U.S. adults with type 1 diabetes","volume":"176","author":"Fang M","year":"2023","journal-title":"Ann Intern Med"},{"key":"e_1_2_10_3_1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1089\/dia.2018.0384","article-title":"State of type 1 diabetes management and outcomes from the T1D exchange in 2016\u20132018","volume":"21","author":"Foster NC","year":"2019","journal-title":"Diabetes Technol Ther"},{"key":"e_1_2_10_4_1","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCULATIONAHA.111.077487","article-title":"The effect of excess weight gain with intensive diabetes treatment on cardiovascular disease risk factors and atherosclerosis in type 1 diabetes: Results from DCCT\/EDIC","volume":"127","author":"Purnell JQ","year":"2013","journal-title":"Circulation"},{"key":"e_1_2_10_5_1","doi-asserted-by":"crossref","DOI":"10.1111\/dme.14794","article-title":"Weight gain trajectories and obesity rates in intensive and conventional treatments of type 1 diabetes from the DCCT compared with a control population without diabetes","volume":"39","author":"Carlson NE","year":"2022","journal-title":"Diabet Med"},{"key":"e_1_2_10_6_1","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.2337\/diabetes.52.10.2623","article-title":"Relationship of family history of type 2 diabetes, hypoglycemia, and autoantibodies to weight gain and lipids with intensive and conventional therapy in the diabetes control and complications trial","volume":"52","author":"Purnell JQ","year":"2003","journal-title":"Diabetes"},{"key":"e_1_2_10_7_1","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1210\/jc.2011-3172","article-title":"Features of hepatic and skeletal muscle insulin resistance unique to type 1 diabetes","volume":"97","author":"Bergman BC","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_2_10_8_1","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.2337\/db19-0324","article-title":"Iatrogenic hyperinsulinemia, not hyperglycemia, drives insulin resistance in type 1 diabetes as revealed by comparison with GCK\u2010MODY","volume":"68","author":"Gregory JM","year":"2019","journal-title":"Diabetes"},{"key":"e_1_2_10_9_1","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2337\/diacare.28.4.777","article-title":"Leisure time physical activity is associated with poor glycemic control in type 1 diabetic women: The FinnDiane study","volume":"28","author":"Wad\u00e9n J","year":"2005","journal-title":"Diabetes Care"},{"key":"e_1_2_10_10_1","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.2337\/dc18-1446","article-title":"BMI, mortality, and cardiovascular outcomes in type 1 diabetes: Findings against an obesity paradox","volume":"42","author":"Edqvist J","year":"2019","journal-title":"Diabetes Care"},{"key":"e_1_2_10_11_1","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-021-01340-4","article-title":"The impact of central obesity on the risk of hospitalization or death due to heart failure in type 1 diabetes: A 16\u2010year cohort study","volume":"20","author":"Parente EB","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"e_1_2_10_12_1","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1093\/eurheartj\/ehaf304","article-title":"Adult\u2010onset type 1 diabetes: Predictors of major cardiovascular events and mortality","volume":"46","author":"Wei Y","year":"2025","journal-title":"Eur Heart J"},{"key":"e_1_2_10_13_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2022.109211","article-title":"Changes of insulin resistance status and development of complications in type 1 diabetes mellitus: Analysis of DCCT\/EDIC study","volume":"184","author":"Mao Y","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"e_1_2_10_14_1","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.2337\/dc20-0433","article-title":"Insulin resistance and risk of major vascular events and all\u2010cause mortality in type 1 diabetes: A 10\u2010year follow\u2010up study","volume":"43","author":"Garofolo M","year":"2020","journal-title":"Diabetes Care"},{"key":"e_1_2_10_15_1","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1530\/EJE-21-0636","article-title":"Insulin resistance and risk of vascular events, interventions and mortality in type 1 diabetes","volume":"185","author":"Helmink MAG","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"e_1_2_10_16_1","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1111\/dom.15545","article-title":"Overweight or obesity, weight variability and the risk of retinopathy in type 1 diabetes","volume":"26","author":"Nystr\u00f6m T","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"e_1_2_10_17_1","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.cgh.2024.09.038","article-title":"Global epidemiology and characteristics of metabolic dysfunction\u2010associated steatotic liver disease in type 1 diabetes mellitus: An updated systematic review and meta\u2010analysis","volume":"23","author":"Souza M","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"e_1_2_10_18_1","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s00125-025-06597-y","article-title":"Liver fat content is not elevated in people with type 1 diabetes: The Maastricht study","volume":"69","author":"Dimitropoulou NM","year":"2026","journal-title":"Diabetologia"},{"key":"e_1_2_10_19_1","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/dom.14911","article-title":"Weight management in young adults with type 1 diabetes: The advancing Care for Type 1 diabetes and obesity network sequential multiple assignment randomized trial pilot results","volume":"25","author":"Igudesman D","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"e_1_2_10_20_1","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1210\/jc.2019-00129","article-title":"Metformin improves peripheral insulin sensitivity in youth with type 1 diabetes","volume":"104","author":"Cree\u2010Green M","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_2_10_21_1","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1161\/CIRCULATIONAHA.118.035525","article-title":"Metformin improves insulin sensitivity and vascular health in youth with type 1 diabetes mellitus: A randomized controlled trial","volume":"138","author":"Bjornstad P","year":"2018","journal-title":"Circulation"},{"key":"e_1_2_10_22_1","doi-asserted-by":"crossref","first-page":"9884","DOI":"10.1038\/s41467-025-65951-1","article-title":"Effect of metformin on insulin resistance in adults with type 1 diabetes: A 26\u2010week randomized double\u2010blind clinical trial","volume":"16","author":"Snaith JR","year":"2025","journal-title":"Nat Commun"},{"key":"e_1_2_10_23_1","volume-title":"Symlin [pramlintide acetate] injection, for subcutaneous use prescribing information","author":"U.S. Food and Drug Administration","year":"2019"},{"key":"e_1_2_10_24_1","doi-asserted-by":"crossref","first-page":"724","DOI":"10.2337\/diacare.25.4.724","article-title":"A randomized study and open\u2010label extension evaluating the long\u2010term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes","volume":"25","author":"Whitehouse F","year":"2002","journal-title":"Diabetes Care"},{"key":"e_1_2_10_25_1","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1464-5491.2004.01319.x","article-title":"Amylin replacement with pramlintide as an adjunct to insulin therapy improves long\u2010term glycaemic and weight control in type 1 diabetes mellitus: A 1\u2010year, randomized controlled trial","volume":"21","author":"Ratner RE","year":"2004","journal-title":"Diabet Med"},{"key":"e_1_2_10_26_1","unstructured":"Pramlintide. Available from:https:\/\/peptidescholar.com\/en\/peptides\/pramlintideDownloaded July 20 2026."},{"key":"e_1_2_10_27_1","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.2337\/dc12-0330","article-title":"Effect of pramlintide on prandial glycemic excursions during closed\u2010loop control in adolescents and young adults with type 1 diabetes","volume":"35","author":"Weinzimer SA","year":"2012","journal-title":"Diabetes Care"},{"key":"e_1_2_10_28_1","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.2337\/dc16-0691","article-title":"Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: The ADJUNCT ONE treat\u2010to\u2010target randomized trial","volume":"39","author":"Mathieu C","year":"2016","journal-title":"Diabetes Care"},{"key":"e_1_2_10_29_1","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.2337\/dc16-0690","article-title":"Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: The ADJUNCT TWO randomized trial","volume":"39","author":"Ahr\u00e9n B","year":"2016","journal-title":"Diabetes Care"},{"key":"e_1_2_10_30_1","article-title":"Semaglutide in adults with type 1 diabetes and obesity","volume":"4","author":"Shah VN","year":"2025","journal-title":"NEJM Evid"},{"key":"e_1_2_10_31_1","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s41591-024-03463-z","article-title":"Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: A double\u2010blind, randomized, crossover trial","volume":"31","author":"Pasqua MR","year":"2025","journal-title":"Nat Med"},{"key":"e_1_2_10_32_1","doi-asserted-by":"crossref","first-page":"718","DOI":"10.2337\/dc25-2249","article-title":"Effect of semaglutide on insulin dose reduction in adults with type 1 diabetes and obesity using automated insulin delivery systems: ADJUST\u2010T1D post hoc analysis","volume":"49","author":"Karakus KE","year":"2026","journal-title":"Diabetes Care"},{"key":"e_1_2_10_33_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/dia.2024.0328","article-title":"Effectiveness of semaglutide and tirzepatide in overweight and obese adults with type 1 diabetes","volume":"27","author":"Snell\u2010Bergeon JK","year":"2025","journal-title":"Diabetes Technol Ther"},{"key":"e_1_2_10_34_1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/15209156251362497","article-title":"Real\u2010world evidence of the effect of adjunctive semaglutide on weight change, glycemic control, and metabolic dysfunction\u2010associated steatotic liver disease in people with type 1 diabetes","volume":"28","author":"Mertens J","year":"2026","journal-title":"Diabetes Technol Ther"},{"key":"e_1_2_10_35_1","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1515\/jpem-2025-0568","article-title":"GLP\u20101 receptor agonists reduce body mass index and total daily insulin dose in youth with type 1 diabetes: A retrospective cohort study","volume":"39","author":"Gonzalez F","year":"2026","journal-title":"J Pediatr Endocrinol Metab"},{"key":"e_1_2_10_36_1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2337\/dc25-2379","article-title":"Tirzepatide in adults with type 1 diabetes: A phase 2 randomized placebo\u2010controlled clinical trial","volume":"49","author":"Snaith JR","year":"2026","journal-title":"Diabetes Care"},{"key":"e_1_2_10_37_1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.mayocp.2024.07.006","article-title":"Effect of tirzepatide on body weight and diabetes control in adults with type 1 diabetes and overweight or obesity","volume":"100","author":"Gutierrez RR","year":"2025","journal-title":"Mayo Clin Proc"},{"key":"e_1_2_10_38_1","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1089\/dia.2024.0481","article-title":"Cardiovascular and renal biomarkers in overweight and obese adults with type 1 diabetes treated with tirzepatide for 21 months","volume":"27","author":"Garg SK","year":"2025","journal-title":"Diabetes Technol Ther"},{"key":"e_1_2_10_39_1","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1038\/s41591-026-04274-0","article-title":"Glucagon\u2010like peptide\u20101 receptor agonists for major cardiovascular and kidney outcomes in type 1 diabetes","volume":"32","author":"Xu Y","year":"2026","journal-title":"Nat Med"},{"key":"e_1_2_10_40_1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/15209156251403555","article-title":"All\u2010cause mortality and health care resource utilization in patients with type 1 diabetes treated with glucagon\u2010like peptide 1 receptor agonists\/glucose\u2010dependent insulinotropic polypeptide","volume":"28","author":"Garg S","year":"2026","journal-title":"Diabetes Technol Ther"},{"key":"e_1_2_10_41_1","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.2337\/dc18-1087","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: The DEPICT\u20101 52\u2010week study","volume":"41","author":"Dandona P","year":"2018","journal-title":"Diabetes Care"},{"key":"e_1_2_10_42_1","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1111\/dom.14060","article-title":"Long\u2010term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: The DEPICT\u20102 study","volume":"22","author":"Mathieu C","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"e_1_2_10_43_1","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.2337\/dc18-1749","article-title":"Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: The EASE trials","volume":"41","author":"Rosenstock J","year":"2018","journal-title":"Diabetes Care"},{"key":"e_1_2_10_44_1","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.2337\/dc18-0343","article-title":"Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: The north American inTandem1 study","volume":"41","author":"Buse JB","year":"2018","journal-title":"Diabetes Care"},{"key":"e_1_2_10_45_1","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1210\/clinem\/dgac618","article-title":"Clinical and safety outcomes with GLP\u20101 receptor agonists and SGLT2 inhibitors in type 1 diabetes: A real\u2010world study","volume":"108","author":"Edwards K","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_2_10_46_1","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1111\/dom.16149","article-title":"Effectiveness of add\u2010on therapy with SGLT2 inhibitors or GLP\u20101 receptor agonists in adults with type 1 diabetes: A prospective DPV registry study","volume":"27","author":"Baechle C","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"e_1_2_10_47_1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.2744","article-title":"SGLT2 inhibitor\u2010associated ketoacidosis vs type 1 diabetes\u2010associated ketoacidosis","volume":"7","author":"Umapathysivam MM","year":"2024","journal-title":"JAMA Netw Open"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1177\/15209156261420167"},{"key":"e_1_2_10_49_1","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","article-title":"Once\u2010weekly cagrilintide for weight management in people with overweight and obesity: A multicentre, randomised, double\u2010blind, placebo\u2010controlled and active\u2010controlled, dose\u2010finding phase 2 trial","volume":"398","author":"Lau DCW","year":"2021","journal-title":"Lancet"},{"key":"e_1_2_10_50_1","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","article-title":"Efficacy and safety of co\u2010administered once\u2010weekly cagrilintide 2.4 mg with once\u2010weekly semaglutide 2.4 mg in type 2 diabetes: A multicentre, randomised, double\u2010blind, active\u2010controlled, phase 2 trial","volume":"402","author":"Frias JP","year":"2023","journal-title":"Lancet"},{"key":"e_1_2_10_51_1","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/dom.14302","article-title":"ADO09, a co\u2010formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes","volume":"23","author":"Andersen G","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"e_1_2_10_52_1","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1111\/dom.14972","article-title":"A co\u2010formulation of pramlintide and insulin A21G improves postprandial glucose and short\u2010term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes","volume":"25","author":"Andersen G","year":"2023","journal-title":"Diabetes Obes Metab"}],"container-title":["Journal of Diabetes Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdi.70427","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdi.70427","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdi.70427","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:43:17Z","timestamp":1788273797000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdi.70427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":51,"alternative-id":["10.1111\/jdi.70427"],"URL":"https:\/\/doi.org\/10.1111\/jdi.70427","archive":["Portico"],"relation":{},"ISSN":["2040-1116","2040-1124"],"issn-type":[{"value":"2040-1116","type":"print"},{"value":"2040-1124","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"assertion":[{"value":"2026-08-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"jdi.70427"}}